Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).

Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J.

Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422. [Epub ahead of print]

PMID:
26704148
2.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.

PMID:
26575258
3.

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.

4.

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16.

PMID:
26569658
5.

Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes.

Herring R, Knight R, Shojaee-Moradie F, Johnsen S, Umpleby AM, Jackson N, Jones R, Dijk DJ, Russell-Jones DL.

Diabetes Obes Metab. 2015 Nov;17(11):1100-3. doi: 10.1111/dom.12553. Epub 2015 Sep 29.

PMID:
26272173
6.

SGLT inhibition and euglycaemic diabetic ketoacidosis.

Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R.

Lancet Diabetes Endocrinol. 2015 Jul;3(7):503-4. doi: 10.1016/S2213-8587(15)00204-1. Epub 2015 May 27. No abstract available.

PMID:
26025388
7.

Comparison of Whole Eye versus First-Surface Astigmatism in Down Syndrome.

Knowlton R, Marsack JD, Leach NE, Herring RJ, Anderson HA.

Optom Vis Sci. 2015 Jul;92(7):804-14. doi: 10.1097/OPX.0000000000000620.

PMID:
26002006
8.

Determination of three-dimensional strain state in crystals using self-interfered split HOLZ lines.

Herring R, Norouzpour M, Saitoh K, Tanaka N, Tanji T.

Ultramicroscopy. 2015 Sep;156:37-40. doi: 10.1016/j.ultramic.2015.04.013. Epub 2015 May 6.

PMID:
25978671
9.

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD.

JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.

PMID:
25942724
10.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD; UNITY-1 Study Group.

JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860.

PMID:
25942723
11.

Vegetarian dietary patterns and the risk of colorectal cancers.

Orlich MJ, Singh PN, Sabaté J, Fan J, Sveen L, Bennett H, Knutsen SF, Beeson WL, Jaceldo-Siegl K, Butler TL, Herring RP, Fraser GE.

JAMA Intern Med. 2015 May;175(5):767-76. doi: 10.1001/jamainternmed.2015.59.

12.

Effect of subcutaneous insulin detemir on glucose flux and lipolysis during hyperglycaemia in people with type 1 diabetes.

Herring RA, Shojaee-Moradie F, Umpleby AM, Jones R, Jackson N, Russell-Jones DL.

Diabetes Obes Metab. 2015 May;17(5):459-67. doi: 10.1111/dom.12434. Epub 2015 Feb 1.

PMID:
25580665
13.

Contextual factors influencing health-related quality of life in African American and Latina breast cancer survivors.

Miller AM, Ashing KT, Modeste NN, Herring RP, Sealy DA.

J Cancer Surviv. 2015 Sep;9(3):441-9. doi: 10.1007/s11764-014-0420-0. Epub 2015 Jan 10.

PMID:
25576214
14.

On risk and regulation: Bt crops in India.

Herring RJ.

GM Crops Food. 2014 Jul 3;5(3):204-9. doi: 10.4161/21645698.2014.950543.

PMID:
25437239
15.

Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.

Yoshida EM, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E.

Hepatology. 2015 Jan;61(1):41-5. doi: 10.1002/hep.27366. Epub 2014 Nov 24.

PMID:
25314116
16.

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M; EPE-A Study Group.

Gastroenterology. 2014 Aug;147(2):377-84.e1. doi: 10.1053/j.gastro.2014.04.046. Epub 2014 May 9.

PMID:
24818764
17.

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study.

N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.

18.

Using the theory of planned behavior to explore attitudes and beliefs about dietary supplements among HIV-positive Black women.

Lino S, Marshak HH, Herring RP, Belliard JC, Hilliard C, Campbell D, Montgomery S.

Complement Ther Med. 2014 Apr;22(2):400-8. doi: 10.1016/j.ctim.2014.03.002. Epub 2014 Mar 12.

PMID:
24731912
19.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators.

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.

20.

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators.

N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk